Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts
نویسندگان
چکیده
منابع مشابه
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.
The efficacy of azacitidine has been demonstrated in acute myeloid leukemia (AML) patients with 20-30% bone marrow (BM) blasts, but limited data is available on patients with ≥30% blasts. We analyzed 55 newly diagnosed AML patients, treated with azacitidine. The overall response rate was 42%. Median overall survival (OS) was 12.3 months. We confirmed poor-risk cytogenetics, therapy-related AML,...
متن کاملInternational phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.
This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and safety vs conventional care regimens (CCRs) in 488 patients age ≥65 years with newly diagnosed acute myeloid leukemia (AML) with >30% bone marrow blasts. Before randomization, a CCR (standard induction chemotherapy, low-dose ara-c, or supportive care only) was preselected for each patient. Patients then w...
متن کاملDe novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 4...
متن کاملEvaluation of ATG7 and Light Chain 3 (LC3) Autophagy Genes Expression in Newly Diagnosed AML Patients
Evaluation of ATG7 and LC3 Autophagy Genes Expression in Newly Diagnosed AML patients Background and aim: Autophagy, known as cell death type II, is a housekeeping pathway that currently has been worked on in matters of tumorigenesis and leukemogenesis. Therefore, in this study expression levels of ATG7 and LC3 as two key genes are targeted in AML patients. Material and method: This...
متن کاملEvaluation of ATG7 and Light Chain 3 (LC3) Autophagy Genes Expression in Newly Diagnosed AML Patients
Evaluation of ATG7 and LC3 Autophagy Genes Expression in Newly Diagnosed AML patients Background and aim: Autophagy, known as cell death type II, is a housekeeping pathway that currently has been worked on in matters of tumorigenesis and leukemogenesis. Therefore, in this study expression levels of ATG7 and LC3 as two key genes are targeted in AML patients. Material and method: This...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Leukemia Research
سال: 2013
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2013.03.022